Analytical methods
Common impurities in synthetic peptides
Most synthetic peptides are made by solid-phase synthesis, one amino acid at a time. Each step that doesn't go to completion leaves a predictable kind of impurity, and most of them can be recognised in HPLC and MS data.
Why impurities are expected
In solid-phase peptide synthesis (SPPS), each amino acid is coupled to a growing chain and then deprotected before the next coupling. Even with coupling efficiencies above 99%, small losses at every step add up over a long sequence. Purification by preparative HPLC removes most by-products, but closely related species can remain. That is why a purity figure always comes with a method.
The main impurity types
| Impurity | How it forms | What it looks like in the data |
|---|---|---|
| Deletion sequences | A coupling step fails, so one residue is missing from an otherwise complete chain | MS: mass lower than target by one residue's mass. HPLC: often elutes close to the main peak |
| Truncated sequences | Chains stop growing early (often after capping of unreacted sites) | MS: shorter fragments. HPLC: usually well separated from the main peak |
| Incomplete deprotection | A side-chain protecting group survives the final cleavage | MS: mass higher than target by the protecting group's mass |
| Oxidation | Methionine (and sometimes tryptophan or cysteine) oxidises during synthesis, handling or storage | MS: +16 Da per oxidised methionine. HPLC: typically elutes slightly earlier |
| Racemisation | An amino acid converts partly to its mirror-image (D) form during coupling | MS: same mass as the target, so it is invisible to MS alone. HPLC: may appear as a shoulder or close peak |
| Deamidation | Asparagine or glutamine side chains convert to acids | MS: +1 Da (hard to resolve at low resolution). HPLC: a nearby peak |
Reading a COA with impurities in mind
- A single HPLC purity figure doesn't tell you which impurities are present. A chromatogram, ideally with LC-MS peak assignments, does.
- Same-mass impurities (racemisation, some isomers) need chromatographic separation; MS identity alone can't exclude them.
- For sensitive assays, ask whether the main impurities have been identified and at what level.
Related: Peptide purity: HPLC and mass spectrometry explained.
Further reading
Sources and further reading
- United States Pharmacopeia, General Chapter <1503> Quality Attributes of Synthetic Peptide Drug Substances.
- ICH Q6B, Specifications for Biotechnological/Biological Products.
- Standard SPPS references (Fmoc/tBu chemistry) from major peptide-synthesis reagent manufacturers.
Frequently asked questions
Why do synthetic peptides contain impurities?
In solid-phase synthesis each coupling and deprotection step that does not go to completion leaves a predictable by-product, and small losses add up over a long sequence. Preparative HPLC removes most but not all.
How does a deletion sequence show up in the data?
In MS as a mass lower than the target by one residue mass, and in HPLC often as a peak close to the main one.
Which impurities cannot be seen by mass spectrometry alone?
Same-mass impurities such as racemised (D-amino acid) forms and some isomers. They need chromatographic separation.
What does oxidation look like?
About +16 Da per oxidised methionine in MS, and typically a slightly earlier-eluting peak in HPLC.